![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 03, 2015 12:25:40 PM
Utibron Neohaler--Courtesy of Novartis
Novartis ($NVS) announced FDA approval last week of its Utibron Neohaler as a long-term maintenance treatment for COPD via the delivery of the bronchodilating agents indacaterol and glycopyrrolate.
In addition, the agency approved the use of glycopyrrolate inhalation powder as a monotherapy, which will be delivered using the Seebri Neohaler. Both combination products will hit the market in early 2016, according to a company release.
The approval comes after a trial of 2,654 patients with COPD that consisted of two 12-week efficacy studies and a 52-week safety study, the release notes. Novartis notes that the approval does not cover asthma, and Utibron is not meant to replace rescue inhalers for sudden attacks.
"Patients have told us about the tremendous impact their COPD can have on everyday activities," said Christi Shaw, Novartis' U.S. country head, in a statement. "With this approval, the COPD community now has a new medicine that can help so many patients by improving not only their symptoms, but also their health-related quality of life. This means the possibility of doing things that matter to them."
Novartis says the Neohaler line of inhalers generates low resistance during delivery, making it easy to use.
Patients are instructed to insert an Utibron capsule inside the inhaler and then pierce it by squeezing buttons on the side of the device. Then, patients must put their mouth on the mouthpiece, inhale and hold their breath for 5 to 10 seconds. Once the capsule is empty of powder (this could take more than one breath), it's time to finish the 13-step process by removing the capsule from the inhaler, according to the product website.
Unfortunately, proper breathing technique and usage of inhalers have been shown to be challenging for patients, making simplification a drug delivery challenge for the future.
Novartis says almost 27 million Americans have COPD, making it the third leading cause of death in the U.S. Novartis hopes to grab a large share of a market expected to reach $14 billion by 2018.
The Utibron will compete with GlaxoSmithKline's ($GSK) Anoro and Breo Ellipta, as well as Boehringer's Stiolto Respimat in the combination drug COPD arena.
Recent NVS News
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:30:06 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/13/2024 08:31:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 07:30:35 PM
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) • PR Newswire (US) • 08/07/2024 11:38:00 PM
- Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News • IH Market News • 08/06/2024 09:44:42 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/02/2024 08:30:48 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:30:53 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/31/2024 08:30:44 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/30/2024 08:30:54 PM
- Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:54 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/25/2024 08:30:58 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/18/2024 08:30:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:09:04 AM
- TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge • IH Market News • 07/18/2024 09:53:54 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/11/2024 08:30:53 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/17/2024 08:30:09 PM
- Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio • PR Newswire (US) • 05/25/2024 10:15:00 AM
- Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo • PR Newswire (US) • 05/25/2024 10:00:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/24/2024 08:31:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 04:42:04 PM
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/07/2024 11:00:11 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) • PR Newswire (US) • 04/15/2024 06:00:00 PM
FEATURED ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM